Clinical Trials Directory

Trials / Unknown

UnknownNCT03675347

Recurrent Events After Percutaneous Coronary INterventio for ACS

Incidence, Predictors and impAct on General Population of Recurrent Events After Percutaneous Coronary INterventio for ACS: the AGAIN a Multicenter Study

Status
Unknown
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
A.O.U. Città della Salute e della Scienza · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers

Summary

Patients undergoing PCI for ACS are exposed to a significant ischemic and bleeding risk. The aim of our study is instead to analyze in detail the rates of recurrent events, but also their predictors and impact on outcomes, in a population of unselected real life patients treated with PCI for ACS discharged on either Clopidogrel, Prasugrel or Ticagrelor who already experienced an adverse event during the first year of follow up.

Detailed description

Patients undergoing PCI for ACS are exposed to a significant ischemic and bleeding risk. The rate, predictors and outcomes of an adverse event in this population has been already investigated. However, to the best of our knowledge, only two papers took specifically in analysis rates of recurrence after a first event; the first is a recently published article by Giustino et al; it took in consideration recurrent events in a selected population of patients with ST-elevation Myocardial Infarction (STEMI) participating in the HORIZONS-AMI Trial, discharged on Aspirin and Clopidogrel, analyzing their incidence in the first year of follow-up. The second is a paper by Fanaroff et al which primarily focused on the factors leading to a DAPT intensification in patients with recurrent events. The aim of our study is instead to analyze in detail the rates of recurrent events, but also their predictors and impact on outcomes, in a population of unselected real life patients treated with PCI for ACS discharged on either Clopidogrel, Prasugrel or Ticagrelor who already experienced an adverse event during the first year of follow up.

Conditions

Interventions

TypeNameDescription
OTHERangioplastyangioplasty

Timeline

Start date
2018-10-01
Primary completion
2019-11-01
Completion
2019-11-01
First posted
2018-09-18
Last updated
2018-09-18

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT03675347. Inclusion in this directory is not an endorsement.